Targovax, a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announces that members of its senior management team will participate in the following life sciences and investor conferences:
INVESTOR/PARTNERING CONFERENCES
Sachs Associates 9th Annual ELSCEO Forum & Exhibition
Zurich, 15 March, 2016
Participants: Gunnar Gårdemyr (CEO), Øystein Soug (CFO) and Magnus Jäderberg (CMO)
Presentation time: 10:45
Venue: Hilton Zurich Airport Hotel
BIO-EUROPE Spring 2016
Stockholm, 5-6 April, 2016
Participants: Gunnar Gårdemyr (CEO) and Peter Skorpil (VP Business Development)
BioEquity
Copenhagen, 10-11 May, 2016
Participants: Gunnar Gårdemyr (CEO), Øystein Soug (CFO) and Magnus Jäderberg (CMO)
BIO International Convention
San Francisco, 6-9 June, 2016
Participants: Gunnar Gårdemyr (CEO) and Peter Skorpil (VP Business Development)
SCIENTIFIC CONFERENCES
Royal Swedish Academy of Engineering Sciences
Stockholm, 16 May, 2016
Participants: Magnus Jäderberg (CMO)
ASCO
Chicago, 3-7 June, 2016
Participants: Magnus Jäderberg (CMO)
The Presentations will be available to download at targovax.com/investors/presentations following the event.
For further information, please contact:
Gunnar Gårdemyr
CEO
Phone: +41 798 340 585
Email: ggardemyr@targovax.com
Øystein Soug
CFO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com